

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4602832

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BRUCE A. ANDRIEN JR.	04/06/2015
DOUGLAS L. SHERIDAN	04/01/2015
PAUL P. TAMBURINI	03/26/2015
RECEIVING PARTY DATA	
Name:	ALEXION PHARMACEUTICALS, INC.
Street Address:	100 COLLEGE ST.
City:	NEW HAVEN
State/Country:	CONNECTICUT
Postal Code:	06510
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15708658
CORRESPONDENCE DATA	
Fax Number:	(617)742-4214
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 217-4700
Email:	ipboston.docketing@nelsonmullins.com, danielle.gamache@nelsonmullins.com
Correspondent Name:	NELSON MULLINS RILEY & SCARBOROUGH LLP
Address Line 1:	ONE POST OFFICE SQUARE
Address Line 4:	BOSTON, MASSACHUSETTS 02109-2127
ATTORNEY DOCKET NUMBER:	AXJ-186DV2CN4
NAME OF SUBMITTER:	JILL GORNY SLOPER, ESQ.
SIGNATURE:	/Jill Gorny Sloper, Esq./
DATE SIGNED:	09/20/2017
Total Attachments: 4	
source=AXJ_186DV2CN4_Assignment#page1.tif	
source=AXJ_186DV2CN4_Assignment#page2.tif	
source=AXJ_186DV2CN4_Assignment#page3.tif	

ASSIGNMENT BY INVENTORS

WE, Bruce A. ANDRIEN, Jr.; Douglas L. SHERIDAN; and Paul P. TAMBURINI, of Guilford, Connecticut; Branford, Connecticut; and Kensington, Connecticut, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 352 Knotter Drive, Cheshire, Connecticut 06410, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 14/641,026, filed on March 6, 2015; and International Application No. PCI/US2015/019225, filed on March 6, 2015

This application claims the benefit of the following provisional application(s):

☒ Provisional Application No. 61/949,932, filed on March 7, 2014

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.

06 Apr 15

Date

Bruce A. Andrien Jr.

Bruce A. Andrien, Jr.

Witness:

April 6, 2015

Date

Darlene Swartz

Date

Douglas L. Sheridan

Witness:

Date

Date

Paul P. Tamburini

Witness:

Date

ASSIGNMENT BY INVENTORS

WE, Bruce A. ANDRIEN, Jr.; Douglas L. SHERIDAN; and Paul P. TAMBURINI, of Guilford, Connecticut; Branford, Connecticut; and Kensington, Connecticut, respectively, for good and valuable consideration paid to us by

Alexion Pharmaceuticals, Inc.

a Corporation of Delaware, having its principal place of business at 352 Knotter Drive, Cheshire, Connecticut 06410, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Alexion Pharmaceuticals, Inc.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

ANTI-CS ANTIBODIES HAVING IMPROVED PHARMACOKINETICS

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 14/641,026, filed on March 6, 2015; and International Application No. PCT/US2015/019225, filed on March 6, 2015

This application claims the benefit of the following provisional application(s):

☒ Provisional Application No. 61/949,932, filed on March 7, 2014

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors and assigns.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.


Date

Bruce A. Andrien, Jr.

Witness:


Date

April 1, 2015
Date



Douglas L. Sheridan

Witness:

4/1/2015
Date



3-26-15
Date


Paul P. Tamburini

Witness:

3/26/2015
Date

